41 results
Page 2 of 3
8-K
EX-99.1
gl63062
14 Jun 21
Cassava Sciences Announces the Appointment of
4:14pm
8-K
EX-99.1
ftlgrxfll7u4
21 Apr 21
Cassava Sciences Reports First Quarter 2021 Financial Results and Announces Guidance on Clinical Data Release
8:45am
8-K
EX-10.1
xt2 0ny2ep
11 Mar 21
Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam
4:59pm
8-K
EX-99.1
cvpz30bjfvxrw gnt0x
12 Feb 21
Cassava Sciences Announces $200 Million Registered Direct Offering of Common Stock
5:09pm
8-K
EX-99.2
gkmpa8gxe68
12 Feb 21
Cassava Sciences Announces $200 Million Registered Direct Offering of Common Stock
5:09pm
8-K
EX-99.1
txfnqg9ml1o05imykxs
8 Feb 21
Regulation FD Disclosure
4:09pm
8-K
EX-99.2
mr98zd5qzw
8 Feb 21
Regulation FD Disclosure
4:09pm
8-K
EX-99.1
urt5ska5 a951f
6 Jan 21
Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer
4:39pm
8-K
EX-99.1
dhays
13 Nov 20
Cassava Sciences Announces Proposed Public Offering of Common Stock
4:36pm
8-K
EX-99.2
xv8e3l b24
13 Nov 20
Cassava Sciences Announces Proposed Public Offering of Common Stock
4:36pm
8-K
EX-99.1
c2o151lf4 vvv91
9 Nov 20
Cassava Sciences Reports Third Quarter 2020 Financial Results
8:30am
8-K
EX-99.2
hdhh4gr
14 Sep 20
Regulation FD Disclosure
4:01pm
8-K
EX-99.1
t9msmiuq exzx
12 Aug 20
Cassava Sciences Announces Second Quarter 2020 Financial Results and Mid-year Business Review
8:30am
8-K
EX-99.2
poe4y
3 Jun 20
Regulation FD Disclosure
5:29pm
8-K
EX-99.1
1grlh
15 May 20
Top-line Results from a Phase 2b Study of PTI-125 in Alzheimer’s Disease Does Not Meet Primary Endpoint
8:20am